These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 37147690)

  • 1. Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial.
    Wieruszewski PM; Bellomo R; Busse LW; Ham KR; Zarbock A; Khanna AK; Deane AM; Ostermann M; Wunderink RG; Boldt DW; Kroll S; Greenfeld CR; Hodges T; Chow JH;
    Crit Care; 2023 May; 27(1):175. PubMed ID: 37147690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Multicenter Observational Cohort Study of Angiotensin II in Shock.
    Smith SE; Newsome AS; Guo Y; Hecht J; McCurdy MT; Mazzeffi MA; Chow JH; Kethireddy S
    J Intensive Care Med; 2022 Jan; 37(1):75-82. PubMed ID: 33231111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin II for the Treatment of Vasodilatory Shock.
    Khanna A; English SW; Wang XS; Ham K; Tumlin J; Szerlip H; Busse LW; Altaweel L; Albertson TE; Mackey C; McCurdy MT; Boldt DW; Chock S; Young PJ; Krell K; Wunderink RG; Ostermann M; Murugan R; Gong MN; Panwar R; Hästbacka J; Favory R; Venkatesh B; Thompson BT; Bellomo R; Jensen J; Kroll S; Chawla LS; Tidmarsh GF; Deane AM;
    N Engl J Med; 2017 Aug; 377(5):419-430. PubMed ID: 28528561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ACE inhibitors and angiotensin receptor blockers differentially alter the response to angiotensin II treatment in vasodilatory shock.
    Leisman DE; Handisides DR; Busse LW; Chappell MC; Chawla LS; Filbin MR; Goldberg MB; Ham KR; Khanna AK; Ostermann M; McCurdy MT; Adams CD; Hodges TN; Bellomo R;
    Crit Care; 2024 Apr; 28(1):130. PubMed ID: 38637829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study.
    Chawla LS; Busse L; Brasha-Mitchell E; Davison D; Honiq J; Alotaibi Z; Seneff MG
    Crit Care; 2014 Oct; 18(5):534. PubMed ID: 25286986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3): protocol for a phase III, double-blind, randomised controlled trial.
    Chawla LS; Russell JA; Bagshaw SM; Shaw AD; Goldstein SL; Fink MP; Tidmarsh GF
    Crit Care Resusc; 2017 Mar; 19(1):43-49. PubMed ID: 28215131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regional differences in the treatment of refractory vasodilatory shock using Angiotensin II in High Output Shock (ATHOS-3) data.
    Abril MK; Khanna AK; Kroll S; McNamara C; Handisides D; Busse LW
    J Crit Care; 2019 Apr; 50():188-194. PubMed ID: 30553989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin II in liver transplantation (AngLT-1): protocol of a randomised, double-blind, placebo-controlled trial.
    Bokoch MP; Tran AT; Brinson EL; Marcus SG; Reddy M; Sun E; Roll GR; Pardo M; Fields S; Adelmann D; Kothari RP; Legrand M
    BMJ Open; 2023 Nov; 13(11):e078713. PubMed ID: 37984940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The scientific rationale and study protocol for the DPP3, Angiotensin II, and Renin Kinetics in Sepsis (DARK-Sepsis) randomized controlled trial: serum biomarkers to predict response to angiotensin II versus standard-of-care vasopressor therapy in the treatment of septic shock.
    Teixeira JP; Perez Ingles D; Barton JB; Dean JT; Garcia P; Kunkel SJ; Sarangarm P; Weiss NK; Schaich CL; Busse LW; Nielsen ND
    Trials; 2024 Mar; 25(1):182. PubMed ID: 38475822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Vasopressors in the Treatment of Vasodilatory Shock: A Systematic Review of Angiotensin II, Selepressin, and Terlipressin.
    Rodriguez R; Cucci M; Kane S; Fernandez E; Benken S
    J Intensive Care Med; 2020 Apr; 35(4):327-337. PubMed ID: 30563433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA Approval of Angiotensin II for the Treatment of Hypotension in Adults with Distributive Shock.
    Senatore F; Jagadeesh G; Rose M; Pillai VC; Hariharan S; Liu Q; McDowell TY; Sapru MK; Southworth MR; Stockbridge N
    Am J Cardiovasc Drugs; 2019 Feb; 19(1):11-20. PubMed ID: 30144016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment With Angiotensin II Is Associated With Rapid Blood Pressure Response and Vasopressor Sparing in Patients With Vasoplegia After Cardiac Surgery: A Post-Hoc Analysis of Angiotensin II for the Treatment of High-Output Shock (ATHOS-3) Study.
    Klijian A; Khanna AK; Reddy VS; Friedman B; Ortoleva J; Evans AS; Panwar R; Kroll S; Greenfeld CR; Chatterjee S
    J Cardiothorac Vasc Anesth; 2021 Jan; 35(1):51-58. PubMed ID: 32868152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin II treatment is associated with improved oxygenation in ARDS patients with refractory vasodilatory shock.
    Leisman DE; Handisides DR; Chawla LS; Albertson TE; Busse LW; Boldt DW; Deane AM; Gong MN; Ham KR; Khanna AK; Ostermann M; McCurdy MT; Thompson BT; Tumlin JS; Adams CD; Hodges TN; Bellomo R
    Ann Intensive Care; 2023 Dec; 13(1):128. PubMed ID: 38103056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the norepinephrine to angiotensin II conversion ratio in patients with vasodilatory hypotension: A post-hoc analysis of the ARAMIS trial.
    See EJ; Chaba A; Spano S; Maeda A; Clapham C; Liu J; Khasin M; Liskaser G; Eastwood G; Bellomo R
    J Crit Care; 2024 Feb; 79():154453. PubMed ID: 37890357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin II for Vasodilatory Hypotension in Patients Requiring Mechanical Circulatory Support.
    Wieruszewski PM; Seelhammer TG; Barreto EF; Busse LW; Chow JH; Davison DL; Gaglani B; Khanna AK; Ten Lohuis CC; Mara KC; Wittwer ED
    J Intensive Care Med; 2023 May; 38(5):464-471. PubMed ID: 36524274
    [No Abstract]   [Full Text] [Related]  

  • 16. Angiotensin II in Vasodilatory Shock.
    Wakefield BJ; Busse LW; Khanna AK
    Crit Care Clin; 2019 Apr; 35(2):229-245. PubMed ID: 30784606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renin and Survival in Patients Given Angiotensin II for Catecholamine-Resistant Vasodilatory Shock. A Clinical Trial.
    Bellomo R; Forni LG; Busse LW; McCurdy MT; Ham KR; Boldt DW; Hästbacka J; Khanna AK; Albertson TE; Tumlin J; Storey K; Handisides D; Tidmarsh GF; Chawla LS; Ostermann M
    Am J Respir Crit Care Med; 2020 Nov; 202(9):1253-1261. PubMed ID: 32609011
    [No Abstract]   [Full Text] [Related]  

  • 18. Role of angiotensin II in treatment of refractory distributive shock.
    Rodriguez R; Fernandez EM
    Am J Health Syst Pharm; 2019 Jan; 76(2):101-107. PubMed ID: 31361800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitivity to angiotensin II dose in patients with vasodilatory shock: a prespecified analysis of the ATHOS-3 trial.
    Ham KR; Boldt DW; McCurdy MT; Busse LW; Favory R; Gong MN; Khanna AK; Chock SN; Zeng F; Chawla LS; Tidmarsh GF; Ostermann M
    Ann Intensive Care; 2019 Jun; 9(1):63. PubMed ID: 31161442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock.
    Bellomo R; Wunderink RG; Szerlip H; English SW; Busse LW; Deane AM; Khanna AK; McCurdy MT; Ostermann M; Young PJ; Handisides DR; Chawla LS; Tidmarsh GF; Albertson TE
    Crit Care; 2020 Feb; 24(1):43. PubMed ID: 32028998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.